D. E. Shaw & Co., Inc. Y M Abs Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding YMAB
# of Institutions
97Shares Held
22.4MCall Options Held
37.4KPut Options Held
48.2K-
Black Rock Inc. New York, NY2.86MShares$32.5 Million0.0% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.23MShares$25.4 Million1.36% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$24.9 Million2.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$23.5 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$20.8 Million0.19% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $497M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...